Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proton-STRIDE in Hepatocellular Carcinoma
NCT06999694Phase 2Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- May 2025
- Primary completion
- May 2030
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab, durvalumab in hepatocellular carcinoma (HCC), sponsored by Chang Gung Memorial Hospital. Started May 2025; status: recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06999694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06999694.